In a subsequent phase 3 trial (ALTA-1L) in patients with ALK + NSCLC who had not previously received an ALK inhibitor, PFS was significantly longer among patients who received brigatinib than among those who received crizotinib (24-month PFS: blinded independent review committee-assessed, 48 % vs. 26 %; hazard ratio, 0.49 [95 % confidence interval [CI], 0.35–0.68]; P < 0.0001; investigator-assessed, 56 % vs. 24 %; 0.43 [0.31–0.61]; P < 0.0001) [6], leading to expanded approval for first-line use. This evidence concerns the gene ALK and non-small cell lung carcinoma.